Celyad SA Company Profile (NASDAQ:CYAD)

About Celyad SA

Celyad SA logoCelyad SA, formerly Cardio3 Biosciences SA is a Belgium-based drug developing company. The Company develops stem cell-based therapies for cardiovascular disease. The Company focuses on developing regenerative therapies to treat illnesses where cardiac tissue is lost due to chronic or acute injury. The Company's product, C-Cure, allows the differentiation of a patient's own cells into cardiopoeitic cells which grow into new heart cells and repair heart muscle. C-Cure consists of autologous adult stem cells guided in vitro to the cardiac lineage before implantation in the failing heart. Furthermore, the Company is involved in the field of immuno-oncology, through its subsidiary, OnCyte.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: N/A
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: CYAD
  • CUSIP:
Key Metrics:
  • Previous Close: $23.00
  • 50 Day Moving Average: $23.41
  • 200 Day Moving Average: $37.01
  • 52-Week Range: $19.81 - $59.50
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -5.61
  • P/E Growth: 0.00
  • Market Cap: $214.20M
  • Outstanding Shares: 9,313,000
Additional Links:
Companies Related to Celyad SA:

Analyst Ratings

Consensus Ratings for Celyad SA (NASDAQ:CYAD) (?)
Ratings Breakdown: 2 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $95.00 (313.04% upside)

Analysts' Ratings History for Celyad SA (NASDAQ:CYAD)
Show:
DateFirmActionRatingPrice TargetDetails
6/7/2016Piper Jaffray Cos.Reiterated RatingOverweight$95.00View Rating Details
12/1/2015Maxim GroupReiterated RatingBuyView Rating Details
(Data available from 9/30/2014 forward)

Earnings

Earnings History for Celyad SA (NASDAQ:CYAD)
No earnings announcements for this company have been tracked by MarketBeat.com

Estimates

Earnings Estimates for Celyad SA (NASDAQ:CYAD)
Current Year EPS Consensus Estimate: $-5.02 EPS
Next Year EPS Consensus Estimate: $-4.10 EPS

Dividends

Dividend History for Celyad SA (NASDAQ:CYAD)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Celyad SA (NASDAQ:CYAD)
No insider trades for this company have been tracked by MarketBeat.com

Headlines

Latest Headlines for Celyad SA (NASDAQ:CYAD)
DateHeadline
News IconCurrent Price Targets For Celyad SA (CYAD) - NewsDen (NASDAQ:CYAD)
newsden.net - September 28 at 9:25 AM
investorplace.com logoBiggest Movers in Manufacturing Stocks Now - IPCI ARDM GLMD PTI - Investorplace.com (NASDAQ:CYAD)
investorplace.com - September 24 at 4:21 PM
News IconCelyad SA (CYAD) Sets New 12-Month Low at $20.90 - NewsDen (NASDAQ:CYAD)
newsden.net - September 20 at 8:11 AM
globenewswire.com logoCELYAD S.A.: Celyad CEO to present at the 2016 Cell & Gene Meeting on the Mesa - GlobeNewswire (press release) (NASDAQ:CYAD)
globenewswire.com - September 15 at 8:40 AM
News IconAnalysts Place Celyad SA (ADR) (NASDAQ:CYAD) Under the Lens of the Microscope - Post News (NASDAQ:CYAD)
www.kentuckypostnews.com - September 15 at 8:40 AM
publicnow.com logoCelyad CEO to present at the 2016 Cell & Gene Meeting on the Mesa (NASDAQ:CYAD)
www.publicnow.com - September 15 at 8:40 AM
News IconAnalysts Take: Celyad SA (ADR) (NASDAQ:CYAD) Projected Earnings & Price Targets - Frisco Fastball (NASDAQ:CYAD)
friscofastball.com - September 14 at 9:46 PM
streetinsider.com logoCelyad SA (CYAD) Announces Completion of NKR-2 Phase I in AML - StreetInsider.com (NASDAQ:CYAD)
www.streetinsider.com - September 10 at 9:09 AM
streetinsider.com logoCelyad SA (CYAD) Announces Completion of NKR-2 Phase I in AML (NASDAQ:CYAD)
www.streetinsider.com - September 9 at 9:23 AM
finance.yahoo.com logoCELYAD S.A.: Celyad completes the NKR-2 Phase I trial with successful safety follow-up of the fourth dose level (NASDAQ:CYAD)
finance.yahoo.com - September 9 at 9:23 AM
publicnow.com logoCelyad completes the NKR-2 Phase I trial with successful safety follow-up of the fourth dose level (NASDAQ:CYAD)
www.publicnow.com - September 9 at 9:23 AM
News IconPlacing Celyad SA (ADR) (NASDAQ:CYAD) Shares Under the Microscope - Post News (NASDAQ:CYAD)
www.kentuckypostnews.com - September 8 at 8:20 AM
publicnow.com logoCongestive Heart Failure Cardiopoietic Regenerative Therapy (CHART-1): Clinical Trial Primary Outcomes (NASDAQ:CYAD)
www.publicnow.com - September 1 at 4:28 PM
News IconStock in Review: Taking a Closer Look at Celyad SA (ADR) (NASDAQ:CYAD) Shares - Post News (NASDAQ:CYAD)
www.kentuckypostnews.com - September 1 at 9:34 AM
publicnow.com logoCelyad appoints Philippe Dechamps as General Counsel and Company Secretary (NASDAQ:CYAD)
www.publicnow.com - September 1 at 9:34 AM
publicnow.com logoProf. Jozef Bartunek presented CHART-1 Phase III Results Outline at ESC 2016 (NASDAQ:CYAD)
www.publicnow.com - August 31 at 9:23 AM
finance.yahoo.com logoCelyad Reports First Half 2016 Financial Results and Operational Progress (NASDAQ:CYAD)
finance.yahoo.com - August 25 at 9:28 AM
News IconSell-side & Crowd View on Celyad SA (ADR) (NASDAQ:CYAD) - Post News (NASDAQ:CYAD)
www.kentuckypostnews.com - August 20 at 5:34 AM
News IconWhat is the Street Saying About Celyad SA (ADR) (NASDAQ:CYAD)? - Post News (NASDAQ:CYAD)
www.kentuckypostnews.com - August 19 at 9:26 AM
News IconCrowd & Street Analysis on Celyad SA (ADR) (NASDAQ:CYAD) - Post News (NASDAQ:CYAD)
www.kentuckypostnews.com - August 18 at 4:35 PM
publicnow.com logoCelyad Letter for Shareholders (NASDAQ:CYAD)
www.publicnow.com - August 8 at 9:22 AM
publicnow.com logoTransparency notification of Medisun International Limited and National Investment Fund Ltd (NASDAQ:CYAD)
www.publicnow.com - August 5 at 4:33 PM
capitalcube.com logoCelyad SA :CYAD-US: Earnings Analysis: For the six months ended December 31, 2015 : July 27, 2016 (NASDAQ:CYAD)
www.capitalcube.com - July 27 at 10:52 AM
capitalcube.com logoCelyad SA :CYAD-BE: Earnings Analysis: For the six months ended December 31, 2015 : July 22, 2016 (NASDAQ:CYAD)
www.capitalcube.com - July 22 at 3:34 AM
capitalcube.com logoCelyad SA :CYAD-BE: Earnings Analysis: 2015 By the Numbers : July 22, 2016 (NASDAQ:CYAD)
www.capitalcube.com - July 22 at 2:11 AM
News IconCelyad SA (ADR) (NASDAQ:CYAD): Sell-Side Ratings and Company Earnings Glance - Engelwood Daily (NASDAQ:CYAD)
www.engelwooddaily.com - July 20 at 9:51 AM
News IconCelyad SA Ads (NASDAQ:CYAD) Sellers Increased By 13.81% Their Shorts - Consumer Eagle (NASDAQ:CYAD)
www.consumereagle.com - July 20 at 9:51 AM
News IconTrading Performance and Target Watch for Celyad SA (ADR) (NASDAQ:CYAD) - Press Telegraph (NASDAQ:CYAD)
presstelegraph.com - July 18 at 9:35 AM
fiscalstandard.com logoCelyad SA (CYAD) Broker Price Targets For The Coming Week - Fiscal Standard (NASDAQ:CYAD)
www.fiscalstandard.com - July 17 at 4:18 PM
4-traders.com logoCelyad : successfully completes safety follow-up of the first patient at the fourth dose level in the NKR-2 Phase I trial (NASDAQ:CYAD)
www.4-traders.com - July 14 at 10:01 PM
msn.com logoCELYAD S.A.: Celyad successfully completes safety follow-up of the first patient at the fourth dose level in the NKR-2 Phase I trial (NASDAQ:CYAD)
www.msn.com - July 14 at 10:01 PM
News IconCelyad SA Ads (NASDAQ:CYAD) Short Interest Increased By 8.67% - Consumer Eagle (NASDAQ:CYAD)
www.consumereagle.com - July 14 at 7:16 AM
publicnow.com logoCelyad successfully completes safety follow-up of the first patient at the fourth dose level in the NKR-2 Phase I trial (NASDAQ:CYAD)
www.publicnow.com - July 14 at 1:48 AM
News IconCelyad SA (ADR) (NASDAQ:CYAD) Earnings Concentration and Analyst Target Watch - Engelwood Daily (NASDAQ:CYAD)
www.engelwooddaily.com - July 12 at 4:41 PM
msn.com logoCELYAD S.A.: Celyad enters into license agreement with ONO PHARMACEUTICAL CO., LTD. to develop allogeneic NKR-2 T-cell immunotherapy (NASDAQ:CYAD)
www.msn.com - July 11 at 4:32 PM
streetinsider.com logoCelyad SA (CYAD) Enters Licensing Agreement with ONO Pharma for NKR-2 T-cell Immunotherapy (NASDAQ:CYAD)
www.streetinsider.com - July 11 at 4:32 PM
streetinsider.com logoCelyad SA (CYAD) Enters Licensing Agreement with ONO Pharma for NKR-2 T-cell Immunotherapy - StreetInsider.com (NASDAQ:CYAD)
www.streetinsider.com - July 11 at 9:20 AM
insidermonkey.com logoWeekly Biotech Report Covering Gilead Sciences, Inc. (GILD) and Celyad SA (ADR) (CYAD) - Insider Monkey (blog) (NASDAQ:CYAD)
www.insidermonkey.com - July 8 at 10:02 AM
News IconWeekly Biotech Report Covering Gilead Sciences, Inc. (GILD) and Celyad SA (ADR) (CYAD) (NASDAQ:CYAD)
feedproxy.google.com - July 7 at 2:52 PM
fiscalstandard.com logoCelyad SA (CYAD) Current Analyst Ratings - Fiscal Standard (NASDAQ:CYAD)
www.fiscalstandard.com - July 7 at 9:47 AM
nasdaq.com logoANTH Dims On BRIGHT-SC Data, CYAD Fails To Chart, LLY Gets FDA Panel Nod - Nasdaq (NASDAQ:CYAD)
www.nasdaq.com - July 1 at 9:39 PM
News IconCelyad SA Ads (NASDAQ:CYAD) Shorted Shares Increased 8.67% After Market Selling - Engelwood Daily (NASDAQ:CYAD)
www.engelwooddaily.com - June 30 at 10:31 AM
fiscalstandard.com logoBrokers Issue Average Price Target Of 87.00 On Celyad SA (CYAD) - Fiscal Standard (NASDAQ:CYAD)
www.fiscalstandard.com - June 30 at 10:31 AM
ftsenews.co.uk logoNew Broker Ratings For Celyad SA (CYAD) - FTSE News (NASDAQ:CYAD)
www.ftsenews.co.uk - June 29 at 9:32 PM
streetinsider.com logoCelyad SA (CYAD) Says CHART-1 Trial Results Not Statistically Significant (NASDAQ:CYAD)
www.streetinsider.com - June 29 at 4:28 PM
benzinga.com logo7 Biggest Mid-Day Losers For Tuesday - Benzinga (NASDAQ:CYAD)
www.benzinga.com - June 28 at 9:39 PM
fiscalstandard.com logoNext Weeks Broker Price Targets For Celyad SA (CYAD) - Fiscal Standard (NASDAQ:CYAD)
www.fiscalstandard.com - June 28 at 9:39 PM
News IconCelyad SA (EBR:CYAD)'s Company Shares Decreased 16.62% After Low Volatility - Press Telegraph (NASDAQ:CYAD)
presstelegraph.com - June 28 at 9:39 PM
streetinsider.com logoCelyad SA (CYAD) Says CHART-1 Trial Results Not Statistically Significant - StreetInsider.com (NASDAQ:CYAD)
www.streetinsider.com - June 28 at 9:39 PM
msn.com logoCELYAD S.A.: Celyad Announces Results for the CHART-1 Phase III Clinical Trial Evaluating C-Cure(R) Cell Therapy (NASDAQ:CYAD)
www.msn.com - June 28 at 4:30 PM

Social

Celyad SA (NASDAQ:CYAD) Chart for Friday, September, 30, 2016


Last Updated on 9/30/2016 by MarketBeat.com Staff